E
Edward Pequignot
Researcher at University of Pennsylvania
Publications - 16
Citations - 2747
Edward Pequignot is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Chimeric antigen receptor & Antigen. The author has an hindex of 9, co-authored 16 publications receiving 1824 citations. Previous affiliations of Edward Pequignot include Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta,Simon F. Lacey,Elena Orlando,Iulian Pruteanu-Malinici,Mercy Gohil,Stefan Lundh,Alina C. Boesteanu,Yan Wang,Roddy S. O’Connor,Wei-Ting Hwang,Edward Pequignot,David E Ambrose,Changfeng Zhang,Nicholas Wilcox,Felipe Bedoya,Corin L. Dorfmeier,Fang Chen,Lifeng Tian,Harit Parakandi,Minnal Gupta,Regina M. Young,F. Brad Johnson,Irina Kulikovskaya,Li Liu,Jun Xu,Sadik H. Kassim,Megan M. Davis,Bruce L. Levine,Noelle V. Frey,Don L. Siegel,Alexander C. Huang,E. John Wherry,Hans Bitter,Jennifer Brogdon,David L. Porter,Carl H. June,J. Joseph Melenhorst +36 more
TL;DR: A mechanistically relevant population of CD27+PD-1–CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control, and new features of CAR T cell biology are uncovered.
Journal ArticleDOI
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey,David T. Teachey,Simon F. Lacey,Pamela A. Shaw,J. Joseph Melenhorst,Shannon L. Maude,Noelle V. Frey,Edward Pequignot,Vanessa E. Gonzalez,Fang Chen,Jeffrey Finklestein,David M. Barrett,Scott L. Weiss,Julie C. Fitzgerald,Robert A. Berg,Richard Aplenc,Colleen Callahan,Susan R. Rheingold,Zhaohui Zheng,Stefan Rose-John,Jason C. White,Farzana Nazimuddin,Gerald Wertheim,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +26 more
TL;DR: The first models that can accurately predict which patients are likely to develop severe CRS before they become critically ill are developed, which improves understanding of CRS biology and may guide future cytokine-directed therapy.
Journal ArticleDOI
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu,Shuguang Jiang,Chongyun Fang,Shiyu Yang,Devvora Olalere,Edward Pequignot,Alexandria P. Cogdill,Na Li,Melissa Ramones,Brian Granda,Li Zhou,Andreas Loew,Regina M. Young,Carl H. June,Yangbing Zhao +14 more
TL;DR: The use of affinity-tuned scFvs offers a strategy to empower wider use of CAR T cells against validated targets widely overexpressed on solid tumors, including those considered undruggable by this approach.
Journal ArticleDOI
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
Fang Chen,David T. Teachey,Edward Pequignot,Noelle V. Frey,David L. Porter,Shannon L. Maude,Stephan A. Grupp,Carl H. June,J. Joseph Melenhorst,Simon F. Lacey +9 more
TL;DR: The importance of assessing the impact of cytokine-blocking agents on accuracy of clinical biomarker assays in other diseases, as drugs targeting TNF-alpha, IL1B, and IL5 are being used more frequently in a large number of diseases, is demonstrated.
Journal ArticleDOI
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Noelle V. Frey,Pamela A. Shaw,Elizabeth O. Hexner,Edward Pequignot,Saar Gill,Selina M. Luger,James K. Mangan,Alison W. Loren,Alexander E. Perl,Shannon L. Maude,Stephan A. Grupp,Nirav N. Shah,Joan Gilmore,Simon F. Lacey,J. Joseph Melenhorst,Bruce L. Levine,Carl H. June,David L. Porter +17 more
TL;DR: Fractionated dosing of CTL019 with intrapatient dose modification optimizes safety without compromising efficacy in adults with r/r ALL.